Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2020
Historique:
pubmed: 15 9 2020
medline: 10 9 2021
entrez: 14 9 2020
Statut: ppublish

Résumé

Few studies have examined patient characteristics and treatment patterns among patients with dementia and agitation in the United States (US). To examine real-world treatment patterns and characteristics of patients with agitation related to dementia who were treated with antipsychotics in US residential care and community-based settings. This retrospective chart review collected US physician-level data from patients 55 to 90 years old initiated on an antipsychotic medication for the treatment of agitation related to dementia from January 2018 to May 2018. Clinical characteristics and treatment patterns were assessed overall and stratified by residential care and community-based settings. A total of 313 participating physicians, 59.5% of whom were primary care physicians, abstracted 801 patient charts (residential care: n = 312; community-based: n = 489). Of patients with agitation who were initiated on an antipsychotic, most patients (74.5%) were initiated within 3 months of the onset of their studied agitation episode, and 62.8% experienced multiple agitation episodes before initiation. While non-pharmacological therapies are recommended first-line approach for agitation in dementia, use of non-pharmacological therapy before initiation of antipsychotics was reported for only 37.8% of patients in residential care and 21.3% in community-based settings. Most patients were initiated on an antipsychotic treatment after multiple episodes of agitation and largely without initial non-pharmacological therapy, suggesting that current treatment guideline recommendations for first-line non-pharmacological intervention may not be adequately followed in clinical practice. Understanding the clinical burden and treatment patterns among dementia patients with agitation is imperative for effective disease management.

Sections du résumé

BACKGROUND
Few studies have examined patient characteristics and treatment patterns among patients with dementia and agitation in the United States (US).
OBJECTIVE
To examine real-world treatment patterns and characteristics of patients with agitation related to dementia who were treated with antipsychotics in US residential care and community-based settings.
METHODS
This retrospective chart review collected US physician-level data from patients 55 to 90 years old initiated on an antipsychotic medication for the treatment of agitation related to dementia from January 2018 to May 2018. Clinical characteristics and treatment patterns were assessed overall and stratified by residential care and community-based settings.
RESULTS
A total of 313 participating physicians, 59.5% of whom were primary care physicians, abstracted 801 patient charts (residential care: n = 312; community-based: n = 489). Of patients with agitation who were initiated on an antipsychotic, most patients (74.5%) were initiated within 3 months of the onset of their studied agitation episode, and 62.8% experienced multiple agitation episodes before initiation. While non-pharmacological therapies are recommended first-line approach for agitation in dementia, use of non-pharmacological therapy before initiation of antipsychotics was reported for only 37.8% of patients in residential care and 21.3% in community-based settings.
CONCLUSION
Most patients were initiated on an antipsychotic treatment after multiple episodes of agitation and largely without initial non-pharmacological therapy, suggesting that current treatment guideline recommendations for first-line non-pharmacological intervention may not be adequately followed in clinical practice. Understanding the clinical burden and treatment patterns among dementia patients with agitation is imperative for effective disease management.

Identifiants

pubmed: 32925028
pii: JAD200127
doi: 10.3233/JAD-200127
pmc: PMC7683079
doi:

Substances chimiques

Antipsychotic Agents 0

Types de publication

Journal Article Observational Study Pragmatic Clinical Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1181-1194

Références

Int J Geriatr Psychiatry. 2017 Feb;32(2):164-174
pubmed: 26889640
Int J Geriatr Psychiatry. 2008 May;23(5):537-45
pubmed: 18058838
Continuum (Minneap Minn). 2018 Jun;24(3, BEHAVIORAL NEUROLOGY AND PSYCHIATRY):783-803
pubmed: 29851878
Int J Psychiatry Clin Pract. 2018 Sep;22(3):232-239
pubmed: 29235398
J Gerontol Nurs. 2008 Dec;34(12):8-15; quiz 16-7
pubmed: 19112999
Expert Opin Pharmacother. 2013 Mar;14(4):459-74
pubmed: 23350964
JAMA. 2002 Apr 24;287(16):2090-7
pubmed: 11966383
Dialogues Clin Neurosci. 2009;11(2):217-28
pubmed: 19585957
Int Psychogeriatr. 2019 Aug;31(8):1137-1149
pubmed: 30334500
Expert Rev Neurother. 2018 Jun;18(6):461-467
pubmed: 29764230
Int Psychogeriatr. 2015 Mar;27(3):385-405
pubmed: 25403309
CNS Drugs. 2020 Mar;34(3):243-268
pubmed: 32052375
Am J Psychiatry. 2016 May 1;173(5):543-6
pubmed: 27133416
J Am Geriatr Soc. 2007 Oct;55(10):1508-16
pubmed: 17727648
Psychiatr Pol. 2016;50(4):679-715
pubmed: 27847922
Int Psychogeriatr. 2019 Jan;31(1):83-90
pubmed: 30068400
Lancet Psychiatry. 2019 Apr;6(4):293-304
pubmed: 30872010
JAMA Psychiatry. 2015 May;72(5):438-45
pubmed: 25786075
Med Care. 2009 Feb;47(2):191-8
pubmed: 19169120
Int Psychogeriatr. 2015 Jan;27(1):7-17
pubmed: 25311499
Am J Psychiatry. 2012 Sep;169(9):900-6
pubmed: 22952071
Expert Opin Pharmacother. 2017 Apr;18(6):611-620
pubmed: 28300462
BMJ Open. 2016 Nov 18;6(11):e013591
pubmed: 27864252
Curr Alzheimer Res. 2016;13(10):1134-44
pubmed: 27137221
Front Neurol. 2018 Dec 13;9:1058
pubmed: 30619031
Int Psychogeriatr. 2019 Mar 11;:1-14
pubmed: 30855002
Innov Aging. 2018 Mar 20;2(1):igy001
pubmed: 30480128
Am J Geriatr Psychiatry. 2010 Oct;18(10):917-27
pubmed: 20808108
Alzheimers Dement (N Y). 2019 Nov 23;5:851-861
pubmed: 31799369
J Am Med Dir Assoc. 2016 Jun 1;17(6):495-500
pubmed: 26944910
Am J Psychiatry. 2015 May;172(5):460-5
pubmed: 25585033
BMC Neurol. 2019 Feb 28;19(1):33
pubmed: 30819136
J Am Med Dir Assoc. 2013 Mar;14(3):161-9
pubmed: 23168112
Am J Psychiatry. 2016 May 1;173(5):441-3
pubmed: 27133400

Auteurs

Myrlene Sanon Aigbogun (MS)

Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.

Martin Cloutier (M)

Analysis Group, Inc., Montreal, Quebec, Canada.

Marjolaine Gauthier-Loiselle (M)

Analysis Group, Inc., Montreal, Quebec, Canada.

Annie Guerin (A)

Analysis Group, Inc., Montreal, Quebec, Canada.

Martin Ladouceur (M)

Analysis Group, Inc., Montreal, Quebec, Canada.

Ross A Baker (RA)

Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.

Michael Grundman (M)

Global R&D Partners, LLC, San Diego, CA, USA.
University of California, San Diego, San Diego, CA, USA.

Ruth A Duffy (RA)

Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.

Ann Hartry (A)

Lundbeck Pharmaceuticals, Deerfield, IL, USA.

Keva Gwin (K)

Lundbeck Pharmaceuticals, Deerfield, IL, USA.

Howard Fillit (H)

Alzheimer's Drug Discovery Foundation, New York, NY, USA.
Mount Sinai School of Medicine, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH